Alcami Capacity Update January 2025: Small Molecule

Alcami is a globally recognized CDMO committed to partnering with clients to bring life-changing medicines to patients. Leveraging industry expertise, a proven regulatory track record, and a focus on excellence, we deliver reliable solutions from discovery to commercialization.

Our formulation development capabilities include innovative oral solid dosage (OSD) forms such as orodispersible tablets (ODTs), minitablets, and controlled-release systems. With advanced technologies like particle size optimization, solubility enhancement, and custom polymer systems, we address diverse therapeutic needs. Alcami’s state-of-the-art OSD development suite ensures seamless scalability from clinical trials to commercialization.

Our facilities support solid-state characterization, non-GMP analytical testing, clinical manufacturing, and stability studies. We handle DEA Schedule I-V materials, Safebridge 3b compounds, and projects requiring Low Humidity Suites (<30% RH). With capacity for commercial blends up to 650 kg and small-scale blistering, we cater to even the most complex requirements.

In addition, Alcami provides comprehensive packaging solutions, including bottling, blistering, vial labeling, and pre-filled syringe services. We offer serialization and aggregation from sellable units to pallets, along with secondary packaging options like cartoning, walleting, and kit assembly. Our expertise in clinical labeling for open, blinded, and double-blinded studies ensures precision and confidentiality.

With cutting-edge capabilities and client-focused solutions, Alcami supports your drug development journey from concept to commercialization, helping you bring transformative therapies to patients with speed and quality.